These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 31085796)
1. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin. Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796 [TBL] [Abstract][Full Text] [Related]
2. Short-form RON (sf-RON) enhances glucose metabolism to promote cell proliferation via activating β-catenin/SIX1 signaling pathway in gastric cancer. Wang Z; Yang Y; Hu S; He J; Wu Z; Qi Z; Huang M; Liu R; Lin Y; Tan C; Xu M; Zhang Z Cell Biol Toxicol; 2021 Feb; 37(1):35-49. PubMed ID: 32399910 [TBL] [Abstract][Full Text] [Related]
3. Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines. Zhou DH; Li C; Yang LN Cancer Cell Int; 2015; 15(1):9. PubMed ID: 25685065 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. Xu XM; Zhou YQ; Wang MH J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878 [TBL] [Abstract][Full Text] [Related]
5. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells. Thangasamy A; Rogge J; Ammanamanchi S J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182 [TBL] [Abstract][Full Text] [Related]
6. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Wang MH; Lao WF; Wang D; Luo YL; Yao HP Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409 [TBL] [Abstract][Full Text] [Related]
7. Chrysin inhibits cell invasion by inhibition of Recepteur d'origine Nantais via suppressing early growth response-1 and NF-κB transcription factor activities in gastric cancer cells. Xia Y; Lian S; Khoi PN; Yoon HJ; Han JY; Chay KO; Kim KK; Jung YD Int J Oncol; 2015 Apr; 46(4):1835-43. PubMed ID: 25625479 [TBL] [Abstract][Full Text] [Related]
8. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492 [TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA targeting of Recepteur d'Origine Nantais induces apoptosis via modulation of nuclear factor-kappaB and Bcl-2 family in gastric cancer cells. Park JS; Park JH; Lee S; Joo YE; Jung YD Oncol Rep; 2010 Sep; 24(3):709-14. PubMed ID: 20664977 [TBL] [Abstract][Full Text] [Related]
10. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757 [TBL] [Abstract][Full Text] [Related]
11. EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells. Park JS; Khoi PN; Joo YE; Lee YH; Lang SA; Stoeltzing O; Jung YD Int J Oncol; 2013 Mar; 42(3):1120-6. PubMed ID: 23337910 [TBL] [Abstract][Full Text] [Related]
12. Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity. Johnson AL; Zinser GM; Waltz SE Oncotarget; 2015 Jun; 6(18):16304-20. PubMed ID: 26008979 [TBL] [Abstract][Full Text] [Related]
13. Macrophage stimulating protein preserves blood brain barrier integrity after intracerebral hemorrhage through recepteur d'origine nantais dependent GAB1/Src/β-catenin pathway activation in a mouse model. Lu T; Wang Z; Prativa S; Xu Y; Wang T; Zhang Y; Yu L; Xu N; Tang J; You W; Chen G; Zhang JH J Neurochem; 2019 Jan; 148(1):114-126. PubMed ID: 30380151 [TBL] [Abstract][Full Text] [Related]
14. RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. Song YA; Park YL; Kim KY; Myung E; Chung CY; Cho SB; Lee WS; Jung YD; Kweon SS; Joo YE Pathol Int; 2012 Feb; 62(2):127-36. PubMed ID: 22243783 [TBL] [Abstract][Full Text] [Related]
15. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505 [TBL] [Abstract][Full Text] [Related]
16. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Xu XM; Wang D; Shen Q; Chen YQ; Wang MH Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025 [TBL] [Abstract][Full Text] [Related]
17. RON alternative splicing regulation in primary ovarian cancer. Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of recepteur d'origine nantais tyrosine kinase and cell invasiveness via early growth response-1 in gastric cancer cells. Lee KE; Park JS; Khoi PN; Joo YE; Lee YH; Jung YD J Cell Biochem; 2012 Apr; 113(4):1217-23. PubMed ID: 22095683 [TBL] [Abstract][Full Text] [Related]
19. Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. Zhou D; Pan G; Zheng C; Zheng J; Yian L; Teng X BMC Cancer; 2008 Nov; 8():353. PubMed ID: 19040718 [TBL] [Abstract][Full Text] [Related]
20. MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation. Yu S; Chen C; Chen M; Liang J; Jiang K; Lou B; Lu J; Zhu X; Zhou D J Exp Clin Cancer Res; 2024 Jan; 43(1):32. PubMed ID: 38268030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]